Search Results
Apr 22, 2026, 07:00 ET Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 05:40 ET Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key
More news about: Hengrui Pharma
Apr 21, 2026, 22:00 ET Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment of cervical cancer has been published in The New England
More news about: Mabwell
Apr 21, 2026, 22:00 ET 邁威生物靶向Nectin-4 ADC（9MW2821）治療宮頸癌的病例報告登上《新英格蘭醫學雜誌》
fuvedotin，研發代號：9MW2821）治療宮頸癌的最新臨床病例報道近日登上國際頂尖醫學期刊《新英格蘭醫學雜誌》（NEJM，影響因子：78.5）。 該文章由宜賓市第二人民醫院腫瘤中心汪善兵主任團隊發表，首次向全球揭示了晚期宮頸癌患者在接受新型Nectin-4 ADC（9MW2821）治療後，出現的罕見肝臟「假性進展」現象。「假性進展（pseudoprogression）」一般指在免疫治療初期腫瘤原有病灶短期內增大或出現新病灶，不伴有疾病惡化，後期病灶表現為穩定或縮小的現象，通常並非真正的腫瘤進展。文章報告了一例晚期轉移性宮頸鱗狀細胞癌患者，此患者既往含鉑化療失敗，未接受過免疫治療。在接受9MW2821治療短短兩個週期後，患者基線轉移病灶顯著縮小，血清鱗狀細胞癌抗原（SCC）更是發生「斷崖式」下降——從37.0
More news about: 邁威生物
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
Apr 20, 2026, 22:54 ET Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Apr 20, 2026, 09:30 ET Hesai Unveils Picasso 6D Full-Color SPAD-SoC, Next-Gen ETX, and Innovations in Spatial Intelligence and Physical AI
lidar technologies. Following the launch of Fermi C500, a RISC-V-based high-performance lidar controller SoC that integrates MCU, FPGA functions, and ADC into a single chip, the company has established full-stack in-house ASIC development capabilities. This technology foundation has already
More news about: Hesai Technology
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
a novel TF-targeting ADC with a potentially superior therapeutic window.ADCE-D01 granted Orphan Drug Designation by U.S. FDA. ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo- I inhibitor payload P1021. uPARAP is a novel endocytic receptor ADC target that is overexpressed
More news about: Adcendo
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
a novel TF-targeting ADC with a potentially superior therapeutic window.ADCE-D01 granted Orphan Drug Designation by U.S. FDA. ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo- I inhibitor payload P1021. uPARAP is a novel endocytic receptor ADC target that is overexpressed
More news about: Adcendo
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
recurrence.viiiAbout PADCEV™ (enfortumab vedotin-ejfv) PADCEV™ (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.ix Nonclinical data suggest
More news about: Astellas Pharma Inc.
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology PlatformAll three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed
More news about: CStone Pharmaceuticals
Apr 19, 2026, 18:00 ET Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA."Across our three ADC programs, we have a
More news about: Whitehawk Therapeutics, Inc.
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
Cancer Research Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using
More news about: Antengene Corporation Limited
Apr 17, 2026, 08:30 ET Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026
IPN01203/STAR0501, being advanced in partnership with Ipsen in the prestigious New Drugs on the Horizon session."Combining invikafusp alfa with ADC-mediated immunogenic tumor killing is a scientifically compelling approach, and it is exciting to see this translate into meaningful clinical responses
More news about: Marengo Therapeutics
Apr 17, 2026, 04:19 ET Piramal Pharma Solutions e Ajinomoto Bio-Pharma Services collaborano per supportare lo sviluppo e la produzione di ADC
centinaia di ADC, realizzato migliaia di lotti e attualmente produce numerosi ADC a uso commerciale. Le attuali attività di ampliamento stanno incrementando la capacità produttiva di Piramal per gli ADC su scala commerciale.La tecnologia AJICAP™ di Ajinomoto supporta lo sviluppo di ADC e linker sito-specifici
More news about: Piramal Pharma Solutions
Apr 16, 2026, 16:05 ET Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR
More news about: Whitehawk Therapeutics, Inc.
Apr 16, 2026, 13:12 ET Piramal Pharma Solutions und Ajinomoto Bio-Pharma Services arbeiten zusammen, um die Entwicklung und Herstellung von ADCs zu unterstützen
Geschwindigkeit herzustellen.Als weltweit erstes von der FDA zugelassenes ADC CDMO bringt Piramal mehr als zwei Jahrzehnte Erfahrung in diesem Bereich mit. Das Unternehmen leistete auch Pionierarbeit bei der kommerziellen ADC-Herstellung und verfügt damit über mehr als 15 Jahre Fachwissen. Piramal verfügt
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:30 ET Piramal Pharma Solutions y Ajinomoto Bio-Pharma Services colaboran en el desarrollo y fabricación de ADC
desarrollado cientos de ADC, completado miles de lotes y actualmente fabrica varios ADC comerciales. Las continuas expansiones están incrementando la capacidad de producción de ADC a escala comercial de Piramal.La tecnología AJICAP™ de Ajinomoto facilita el desarrollo de ADC y tecnologías de enlace
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
manufacture AJICAP™-based products with precision and speed.As the world's first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
manufacture AJICAP™-based products with precision and speed.As the world's first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutionsと味の素バイオファーマサービス、抗体薬物複合体（ADC）製造支援に向けた戦略的コラボレーションを開始
https://www.ajibio-pharma.com/ja/をご覧ください。Piramal Pharma SolutionsについてPiramal Pharma Solutions（PPS）は、医薬品ライフサイクル全体にわたるエンド・ツー・エンドの開発および製造ソリューションを提供するCDMOです。北米、欧州、アジアに展開するグローバルネットワークを通じて、創薬支援、プロセス・製剤開発、治験薬供給、原薬および製剤の商業生産を行っています。また、高活性原薬（HPAPI）、ADC、無菌製剤、ペプチド医薬品などの専門サービスも提供しています。 詳細は
More news about: Piramal Pharma Solutions
Apr 15, 2026, 08:00 ET Wobble Genomics to Present Novel mRNA Sequencing Research at AACR 2026
approach to sequencing full-length mRNA from blood to support antibody-drug conjugate (ADC) therapy selection in breast cancer. Poster: Sequencing Full-Length mRNA in Whole Blood of Breast Cancer Patients for ADC Therapy SelectionSession: Liquid Biopsies: Circulating Nucleic Acids
More news about: Wobble Genomics
Apr 14, 2026, 20:00 ET 沃特世推出業界首款適用於 UHPLC/UPLC 的寬範圍 MALS 分析系統，助力大分子快速表徵
nm 擴展至 500 nm，能可靠地表徵更大、更複雜的分析物，如蛋白質聚集體、病毒載體、脂質奈米顆粒 (LNP) 和先進材料。由於能測定絕對莫耳質量和尺寸，omniDAWN 分析系統減少了對色譜柱校正標準品的依賴，協助使用者更快獲得結果並進行更可靠的比較，從而簡化生物相似藥研究、抗體偶聯藥物 (ADC) 表徵和病毒載體分析等流程。隨著這些藥物和其他先進療法進入開發後期與品質管制階段，實驗室愈加依賴 UHPLC 和 UPLC 系統來滿足不斷提升的通量與分離度需求。沃特世公司分析科學資深副總裁 Rob Carpio 表示：「針對複雜生物製劑及新型療法的 UHPLC 和 UPLC 分離技術發展迅速，但偵測技術一直未能跟上步伐，如今這個局面被打破。omniDAWN
More news about: Waters Corporation
Apr 14, 2026, 09:08 ET Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward INDSHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation
More news about: Phrontline Biopharma
Apr 14, 2026, 08:02 ET GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers
Devices Agency (PMDA) has approved the initiation of a first-in-human (FIH) Phase 1 clinical trial of GNX1021, the company's lead antibody-drug conjugate (ADC) candidate, in patients with advanced gastrointestinal cancers.
More news about: GlycoNex, Inc.